Difference in Protein Expression Profile and Chemotherapy Drugs Response of Different Progression Stages of LNCaP Sublines and Other Human Prostate Cancer Cells

Androgen ablation therapy is the primary treatment for metastatic prostate cancer. However, 80-90% of the patients who receive androgen ablation therapy ultimately develop recurrent tumors in 12-33 months after treatment with a median overall survival time of 1-2 years after relapse. LNCaP is a comm...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Lin, Hui-Ping, Lin, Ching-Yu, Hsiao, Ping-Hsuan, Wang, Horng-Dar, Sheng Jiang, Shih, Hsu, Jong-Ming, Jim, Wai-Tim, Chen, Marcelo, Kung, Hsing-Jien, Chuu, Chih-Pin
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Public Library of Science 2013
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3857776/
https://ncbi.nlm.nih.gov/pubmed/24349321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0082625
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller